Sec Form 4 Filing - Marken James G. @ ANI PHARMACEUTICALS INC - 2024-06-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Marken James G. 2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ ANIP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP OPS & PROD DEV (Last) (First) (Middle) C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST 3. Date of Earliest Transaction (MM/DD/YY) 06/07/2024 (Street) BAUDETTE, MN56623 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/07/2024 M 7,250 A $ 49.51 123,616 ( 1 ) D Common Stock 06/07/2024 M 5,300 A $ 57.06 128,916 D Common Stock 06/07/2024 F 11,087 D $ 67.7 ( 2 ) 117,829 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 49.51 06/07/2024 M 7,250 ( 3 ) 03/30/2027 Common Stock 7,250 $ 49.51 0 D Stock Option (right to buy) $ 57.06 06/07/2024 M 5,300 ( 4 ) 04/05/2028 Common Stock 5,300 $ 57.06 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Marken James G. C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST BAUDETTE, MN56623 SVP OPS & PROD DEV Signatures /s/ James G. Marken, by attorney-in-fact Meredith W. Cook 06/11/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The number of shares beneficially owned by the reporting person is amended in this Form 4 to correct an administrative error in a Form 4 filed on March 9, 2023, which misreported that 1,951 shares were withheld on March 7, 2023 to cover taxes on a vesting of shares on that date, when 1,591 shares were withheld. In correcting this administrative error, the number of shares beneficially owned by the reporting person reflects an increase of 360 shares. ( 2 )The shares were sold in multiple trades at prices ranging from $67.64 to $68.10. The price reported above reflects the weighted average sales price. ( 3 )25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. ( 4 )25% of the total options vested on each of April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.